Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF)'s Wayne Paterson speaks to Proactive about a US$20 million investment from Perceptive Advisors. He says the deal has been in the works for a couple of years and provides a substantial funding runway as it works to bring its durable heart valve technology to market. A phase two trial using Anteris' DurAVR™ solutions in patients with aortic stenosis is slated to kick off this year.
Anteris Technologies secures US$20 million investment from top US healthcare investor
